Zurich-Schlieren, October 31, 2017.  At today’s Extraordinary General Meeting of Molecular Partners (SIX: MOLN), the shareholders of the company approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals, and Patrick Amstutz, CEO of Molecular Partners, as new members of the

Research & Development highlights: MP0250:  Phase 2 study in Multiple Myeloma progressing well and according to plan MP0250:  FDA accepted the company’s IND (submitted in August 2017) for phase 2 study evaluating MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC); on track to dose

Zurich-Schlieren, October 12, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, announced today that the first patient was dosed in the phase 1 clinical study of its oncology asset MP0274.

Zurich-Schlieren, October 9, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today published the Invitation to the Extraordinary General Meeting which will be held on Tuesday, October 31, 2017,

CEO and Co-founder Patrick Amstutz also to stand for election to Board at extraordinary general meeting on October 31, 2017 Zurich-Schlieren, October 3, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*,

Zurich-Schlieren, September 19, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs known as DARPin® therapies, is hosting an R&D update on “The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics.”

Zurich-Schlieren, September 07,  2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies, today announced that Dr. Patrick Amstutz, CEO and Andreas Emmenegger, CFO of Molecular Partners will participate

Research & Development highlights: Abicipar: Allergan completed patient recruitment in both wet AMD phase 3 studies four months ahead of schedule MP0250: First patients dosed in phase 2 Multiple Myeloma study; Trial in progress poster to be presented at ESMO Madrid in September 2017 MP0250: IND

First patient dosed in phase 2 Multiple Myeloma study IND submission to FDA in H2 2017 planned for MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC) Zurich-Schlieren, May 30, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class

Zurich-Schlieren, May 12, 2017.  Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., co-founder of the company, as